Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04789655 · ClinicalTrials.gov registry record · Phase 1
Study of CC-96191 in Participants With Relapsed or Refractory Acute Myeloid Leukemia
A Phase 1 study, sponsored by Celgene.
- Terminated
- Registry status
- Phase 1
- Development phase
- 45
- Enrollment target
NCT04789655 is a Phase 1 study that was terminated before completion, run by Celgene. The registered enrollment target is 45 participants.
The verdict
NCT04789655, a Phase 1 study, was terminated before completion, sponsored by Celgene.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 45 participants
- Enrollment target
Study Summary
This Phase 1, clinical study of CC-96191 will explore the safety, tolerability and preliminary biological and clinical activity of CC-96191 as a single-agent in the setting of Relapsed or refractory acute myeloid leukemia (R/R AML). The dose escalation (Part A) of the study will explore escalating intravenous doses of CC-96191 to estimate the MTD and/or RP2D of CC-96191 as monotherapy. The expansion (Part B), will further evaluate the safety and efficacy of CC-96191 administered at or below the MTD in one or more expansion cohorts in order to determine the RP2D.
Interventions
- DRUG CC-96191
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2021-06-16 |
| Est. Completion | 2025-04-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04789655
The ClinicalTrials.gov registry entry for NCT04789655 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CC-96191 is the first listed.
NCT04789655 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04789655 about?
NCT04789655 is a clinical study titled "Study of CC-96191 in Participants With Relapsed or Refractory Acute Myeloid Leukemia". This Phase 1, clinical study of CC-96191 will explore the safety, tolerability and preliminary biological and clinical activity of CC-96191 as a single-agent in the setting of Relapsed or refractory acute myeloid leukemia (R/R AML). The dose escalation (Part A) of the study will explore escalating ...
What is the current status of trial NCT04789655?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2021-06-16. Estimated completion is 2025-04-14.
What interventions are being tested in trial NCT04789655?
The interventions under investigation include: CC-96191 (DRUG).
Who is sponsoring clinical trial NCT04789655?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.